Cytokinetics director plans 5,000-share sale

Cytokinetics, Inc. (CYTK) received a notice under Rule 144 that director B Lynne Parshall plans to sell up to 5,000 shares of common stock.

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) received a notice under Rule 144 that director B Lynne Parshall plans to sell up to 5,000 shares of common stock. The shares were acquired from the issuer through vesting of restricted stock units during the period from May 15, 2025 through May 14, 2026, and the planned sale will be executed through Morgan Stanley Smith Barney LLC.

Key Figures

Shares to be sold: 5,000 shares of common stock Aggregate market value: $354,550.00 Vesting period for RSUs: 05/15/2025 through 05/14/2026 +1 more

4 metrics

Shares to be sold 5,000 shares of common stock Maximum amount of Cytokinetics, Inc. common shares covered by the Rule 144 notice

Aggregate market value $354,550.00 Aggregate market value listed for the 5,000 shares to be sold

Vesting period for RSUs 05/15/2025 through 05/14/2026 Period during which the restricted stock units vested and from which the shares were acquired

Date of Notice 09/01/2026 Date on which the Rule 144 notice was signed and submitted

Key Terms

Rule 144, Restricted Stock Units, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"The securities to be sold were acquired upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate market value financial

"| 5000 | 354550.00 | 139023418 | 09/01/2026 |"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CYTK?

It discloses that director B Lynne Parshall has filed a notice of proposed sale under Rule 144 for up to 5,000 shares of Cytokinetics, Inc. common stock, to be sold through Morgan Stanley Smith Barney LLC.

How many CYTK shares are covered by this Form 144 notice?

The notice covers up to 5,000 shares of Cytokinetics, Inc. common stock. These shares were acquired upon the vesting of restricted stock units over the period from May 15, 2025 through May 14, 2026.

What is the reported aggregate market value of the CYTK shares in this Form 144?

The Form 144 lists an aggregate market value of $354,550.00 for the 5,000 Cytokinetics, Inc. common shares covered by the notice.

How were the CYTK shares to be sold under Form 144 acquired?

The shares were acquired from Cytokinetics, Inc. upon the vesting of restricted stock units during the period from May 15, 2025 through May 14, 2026.

Which broker is handling the proposed CYTK share sale in this Form 144?

The proposed sale of Cytokinetics, Inc. shares is to be handled through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, NY.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/01/2026 - 04:49 PM EDT Accepted by SEC EDGAR 09/01/2026 - 04:48 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001073385
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CYTOKINETICS, INCORPORATED
SEC File Number	000-50633
Address of Issuer	350 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	6506243000
Name of Person for Whose Account the Securities are To Be Sold	B LYNNE PARSHALL
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5000	354550.00	139023418	09/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2025	Restricted Stock Units	Issuer			5000	05/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 5/15/2025 through 5/14/2026.
Date of Notice	09/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/20/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ B Lynne Parshall
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)